Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclisiran effects on LDL-C and coronary plaque burden by photon-counting CT angiography
2026-526046-28-00Phase 4Authorised
- Sponsor
- Policlinico San Donato
- Start
- Nov 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of inclisiran in Chronic Coronary Syndrome (CCS), atherosclerotic disease and hypercholesterolemia, sponsored by Policlinico San Donato. Primary endpoint: Change in LDL-C level from baseline to 12 months. Planned start Nov 2026; status: authorised.
02
Drugs
inclisiran
03
Conditions
Chronic Coronary Syndrome (CCS)atherosclerotic diseasehypercholesterolemia
Beyond the preview
Go deeper on 2026-526046-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526046-28-00.